Cytochrome P450s: Mechanisms and biological implications in drug metabolism and its interaction with oxidative stress

Current Drug Metabolism

Volumn 15, Issue 7, 2014, Pages 719-742

  Bhattacharyya, Sudip ^a   Sinha, Krishnendu ^a   Sil, Parames C ^a  

^a BOSE INSTITUTE   (India)

Author keywords

Bimodal signals; Cytochrome P450; Drug metabolism; Drug toxicity; Mitochondria; Oxidative stress; Pathophysiology; Reactive metabolites

Indexed keywords

AFLATOXIN; BOCEPREVIR; CYTOCHROME P450; HEAT SHOCK PROTEIN; OXCARBAZEPINE; PARACETAMOL; THALIDOMIDE; WARFARIN; DRUG; XENOBIOTIC AGENT;

ARTICLE; BIOTRANSFORMATION; DRUG METABOLISM; ENDOPLASMIC RETICULUM; ENZYME LOCALIZATION; ENZYME MECHANISM; ENZYME STRUCTURE; HUMAN; MICROSOME; MITOCHONDRION; MOLECULAR INTERACTION; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; ADVERSE DRUG REACTION; ANIMAL; DRUG HYPERSENSITIVITY; GENETICS; METABOLISM;

ANIMALS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG HYPERSENSITIVITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENDOPLASMIC RETICULUM; HUMANS; MITOCHONDRIA; OXIDATIVE STRESS; PHARMACEUTICAL PREPARATIONS; XENOBIOTICS;

EID: 84926364538     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200215666141125121659     Document Type: Article

References (346)

1. Cooper, D.Y.; Levin, S.; Narasimhulu, S.; Rosenthal, O. Photochemical action spectrum of the terminal oxidase of mixed function oxidase systems. Science, 1965, 147, 400-2.
2. Gonzalez, F.J. Molecular genetics of the P-450 superfamily. Pharmacol. Ther.,1990, 45, 1-38.
3. Botham, K.M.; Beckett, G.J.; Percy-Robb, I.W.; Boyd, G.S. Bile acid synthesis in isolated rat liver cells. The effect of 7 alphahydroxycholesterol. Eur. J. Biochem., 1980, 103, 299-305.
4. Danielsson, H.; Einarsson, K.; Johansson, G. Effect of biliary drainage on individual reactions in the conversion of cholesterol to taurochlic acid. Bile acids and steroids 180. Eur. J. Biochem., 1967, 2, 44-9.
5. Estabrook, R.W.; Cooper, D.Y.; Rosenthal, O. The light reversible carbon monoxide inhibition of the steroid c21-hydroxylase system of the adrenal cortex. Biochem. Z., 1963, 338, 741-55.
6. Nebert, D.W.; Dalton, T.P. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat. Rev. Cancer, 2006, 6, 947-60.
7. Ohyama, Y.; Noshiro, M.; Okuda, K. Cloning and expression of cDNA encoding 25-hydroxyvitamin D3 24-hydroxylase. FEBS Lett., 1991, 278, 195-8.
8. Shefer, S.; Hauser, S.; Mosbach, E.H. 7-alpha-hydroxylation of cholestanol by rat liver microsomes. J. Lipid Res., 1968, 9, 328-33.
9. Simpson, E.R.; Boyd, G.S. The cholesterol side-chain cleavage system of bovine adrenal cortex. Eur. J. Biochem., 1967, 2, 275-85.
10. Su, P.; Rennert, H.; Shayiq, R.M.; Yamamoto, R.; Zheng, Y.M.; Addya, S.; Strauss, J.F., 3rd; Avadhani, N.G. A cDNA encoding a rat mitochondrial cytochrome P450 catalyzing both the 26-hydroxylation of cholesterol and 25-hydroxylation of vitamin D3: gonadotropic regulation of the cognate mRNA in ovaries. DNA Cell Biol., 1990, 9, 657-67.
11. Usui, E.; Noshiro, M.; Okuda, K. Molecular cloning of cDNA for vitamin D3 25-hydroxylase from rat liver mitochondria. FEBS Lett., 1990, 262, 135-8.
12. Zangar, R.C.; Davydov, D.R.; Verma, S. Mechanisms that regulate production of reactive oxygen species by cytochrome P450. Toxicol. Appl. Pharmacol., 2004, 199, 316-31.
13. de Groot, M.J. Designing better drugs: predicting cytochrome P450 metabolism. Drug Discov. Today, 2006, 11, 601-6.
14. Sangar, M.C.; Bansal, S.; Avadhani, N.G. Bimodal targeting of microsomal cytochrome P450s to mitochondria: implications in drug metabolism and toxicity. Expert Opin. Drug Metab. Toxicol., 2010, 6, 1231-51.
15. Omura, T. Mitochondrial P450s. Chem. Biol. Interact., 2006, 163, 86-93.
16. Werck-Reichhart, D.; Feyereisen, R. Cytochromes P450: a success story. Genome Biol., 2000, 1, REVIEWS3003.
17. Sono, M.; Roach, M.P.; Coulter, E.D.; Dawson, J.H. Heme-Containing Oxygenases. Chem. Rev., 1996, 96, 2841-2888.
18. Bernhardt, R. Cytochromes P450 as versatile biocatalysts. J. Biotechnol., 2006, 124, 128-45.
19. Gandhi, A.; Moorthy, B.; Ghose, R. Drug disposition in pathophysiological conditions. Curr. Drug Metab., 2012, 13, 1327-44.
20. Williams, J.A.; Hyland, R.; Jones, B.C.; Smith, D.A.; Hurst, S.; Goosen, T.C.; Peterkin, V.; Koup, J.R.; Ball, S.E. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos., 2004, 32, 1201-8.
21. Wienkers, L.C.; Heath, T.G. Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov., 2005, 4, 825-33.
22. Gonzalez, F.J. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat. Res., 2005, 569, 101-10.
23. Guengerich, F.P. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J., 2006, 8, E101-11.
24. Sanderson, J.P.; Naisbitt, D.J.; Park, B.K. Role of bioactivation in drug-induced hypersensitivity reactions. AAPS J., 2006, 8, E55-64.
25. Rendic, S.; Guengerich, F.P. Contributions of human enzymes in carcinogen metabolism. Chem. Res. Toxicol., 2012, 25, 1316-83.
26. Degtyarenko, K.N.; Fabian, P. The directory of P450-containing systems on WorldWide Web. Comput. Appl. Biosci., 1996, 12, 237-40.
27. Rozman, D.; Stromstedt, M.; Tsui, L.C.; Scherer, S.W.; Waterman, M.R. Structure and mapping of the human lanosterol 14alphademethylase gene (CYP51) encoding the cytochrome P450 involved in cholesterol biosynthesis; comparison of exon/intron organization with other mammalian and fungal CYP genes. Genomics, 1996, 38, 371-81.
28. Paquette, S.M.; Bak, S.; Feyereisen, R. Intron-exon organization and phylogeny in a large superfamily, the paralogous cytochrome P450 genes of Arabidopsis thaliana. DNA Cell Biol., 2000, 19, 307-17.
29. Tijet, N.; Helvig, C.; Feyereisen, R. The cytochrome P450 gene superfamily in Drosophila melanogaster: annotation, intron-exon organization and phylogeny. Gene, 2001, 262, 189-98.
30. Williams, P.A.; Cosme, J.; Sridhar, V.; Johnson, E.F.; McRee, D.E. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol. Cell, 2000, 5, 121-31.
31. Rowland, P.; Blaney, F.E.; Smyth, M.G.; Jones, J.J.; Leydon, V.R.; Oxbrow, A.K.; Lewis, C.J.; Tennant, M.G.; Modi, S.; Eggleston, D.S. and others. Crystal structure of human cytochrome P450 2D6. J. Biol. Chem., 2006, 281, 7614-22.
32. Williams, P.A.; Cosme, J.; Vinkovic, D.M.; Ward, A.; Angove, H.C.; Day, P.J.; Vonrhein, C.; Tickle, I.J.; Jhoti, H. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science, 2004, 305, 683-6.
33. Yano, J.K.; Wester, M.R.; Schoch, G.A.; Griffin, K.J.; Stout, C.D.; Johnson, E.F. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J. Biol. Chem., 2004, 279, 38091-4.
34. Williams, P.A.; Cosme, J.; Ward, A.; Angove, H.C.; Matak Vinkovic, D.; Jhoti, H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature, 2003, 424, 464-8.
35. Wester, M.R.; Yano, J.K.; Schoch, G.A.; Yang, C.; Griffin, K.J.; Stout, C.D.; Johnson, E.F. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. J. Biol. Chem., 2004, 279, 35630-7.
36. Caro, A.A.; Cederbaum, A.I. Role of calcium and calciumactivated proteases in CYP2E1-dependent toxicity in HEPG2 cells. J. Biol. Chem., 2002, 277, 104-13.
37. Caro, A.A.; Cederbaum, A.I. Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu. Rev. Pharmacol. Toxicol., 2004, 44, 27-42.
38. Thum, T.; Borlak, J. Cytochrome P450 mono-oxygenase gene expression and protein activity in cultures of adult cardiomyocytes of the rat. Br. J. Pharmacol., 2000, 130, 1745-52.
39. Oyekan, A.O.; McAward, K.; Conetta, J.; Rosenfeld, L.; McGiff, J.C. Endothelin-1 and CYP450 arachidonate metabolites interact to promote tissue injury in DOCA-salt hypertension. Am. J. Physiol., 1999, 276, R766-75.
40. Scarborough, P.E.; Ma, J.; Qu, W.; Zeldin, D.C. P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metab. Rev., 1999, 31, 205-34.
41. Ding, X.; Kaminsky, L.S. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol., 2003, 43, 149-73.
42. Avadhani, N.G.; Sangar, M.C.; Bansal, S.; Bajpai, P. Bimodal targeting of cytochrome P450s to endoplasmic reticulum and mitochondria: the concept of chimeric signals. FEBS J., 2011, 278, 4218-29.
43. Guengerich, F.P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol., 2001, 14, 611-50.
44. Hunter, A.L.; Cruz, R.P.; Cheyne, B.M.; McManus, B.M.; Granville, D.J. Cytochrome p450 enzymes and cardiovascular disease. Can. J. Physiol. Pharmacol., 2004, 82, 1053-60.
45. Glick, B.; Schatz, G. Import of proteins into mitochondria. Annu. Rev. Genet., 1991, 25, 21-44.
46. Yogev, O.; Naamati, A.; Pines, O. Fumarase: a paradigm of dual targeting and dual localized functions. FEBS J., 2011, 278, 4230-42.
47. Vongsamphanh, R.; Fortier, P.K.; Ramotar, D. Pir1p mediates translocation of the yeast Apn1p endonuclease into the mitochondria to maintain genomic stability. Mol. Cell. Biol., 2001, 21, 1647-55.
48. Prabu, S.K.; Anandatheerthavarada, H.K.; Raza, H.; Srinivasan, S.; Spear, J.F.; Avadhani, N.G. Protein kinase A-mediated phosphorylation modulates cytochrome c oxidase function and augments hypoxia and myocardial ischemia-related injury. J. Biol. Chem., 2006, 281, 2061-2070.
49. Kusano, K.; Sakaguchi, M.; Kagawa, N.; Waterman, M.R.; Omura, T. Microsomal p450s use specific proline-rich sequences for efficient folding, but not for maintenance of the folded structure. J. Biochem., 2001, 129, 259-69.
50. Eilers, M.; Schatz, G. Binding of a specific ligand inhibits import of a purified precursor protein into mitochondria. Nature, 1986, 322, 228-32.
51. Swinkels, B.W.; Gould, S.J.; Bodnar, A.G.; Rachubinski, R.A.; Subramani, S. A novel, cleavable peroxisomal targeting signal at the amino-terminus of the rat 3-ketoacyl-CoA thiolase. EMBO. J., 1991, 10, 3255-62.
52. Addya, S.; Anandatheerthavarada, H.K.; Biswas, G.; Bhagwat, S.V.; Mullick, J.; Avadhani, N.G. Targeting of NH2-terminalprocessed microsomal protein to mitochondria: a novel pathway for the biogenesis of hepatic mitochondrial P450MT2. J. Cell Biol., 1997, 139, 589-99.
53. Anandatheerthavarada, H.K.; Vijayasarathy, C.; Bhagwat, S.V.; Biswas, G.; Mullick, J.; Avadhani, N.G. Physiological role of the N-terminal processed P4501A1 targeted to mitochondria in erythromycin metabolism and reversal of erythromycin-mediated inhibition of mitochondrial protein synthesis. J. Biol. Chem., 1999, 274, 6617-6625.
54. Robin, M.A.; Anandatheerthavarada, H.K.; Fang, J.K.; Cudic, M.; Otvos, L.; Avadhani, N.G. Mitochondrial targeted cytochrome P450 2E1 (P450 MT5) contains an intact N terminus and requires mitochondrial specific electron transfer proteins for activity. J. Biol. Chem., 2001, 276, 24680-9.
55. Boopathi, E.; Anandatheerthavarada, H.K.; Bhagwat, S.V.; Biswas, G.; Fang, J.K.; Avadhani, N.G. Accumulation of mitochondrial P450MT2, NH(2)-terminal truncated cytochrome P4501A1 in rat brain during chronic treatment with beta-naphthoflavone. A role in the metabolism of neuroactive drugs. J. Biol. Chem., 2000, 275, 34415-23.
56. Bansal, S.; Liu, C.P.; Sepuri, N.B.; Anandatheerthavarada, H.K.; Selvaraj, V.; Hoek, J.; Milne, G.L.; Guengerich, F.P.; Avadhani, N.G. Mitochondria-targeted cytochrome P450 2E1 induces oxidative damage and augments alcohol-mediated oxidative stress. J. Biol. Chem., 2010, 285, 24609-19.
57. Sabatini, D.D.; Blobel, G.; Nonomura, Y.; Adelman, M.R. Ribosome-membrane interaction: Structural aspects and functional implications. Adv. Cytopharmacol.,1971, 1, 119-29.
58. Shayiq, R.M.; Addya, S.; Avadhani, N.G. Constitutive and inducible forms of cytochrome P450 from hepatic mitochondria. Methods Enzymol., 1991, 206, 587-94.
59. Dasari, V.R.; Anandatheerthavarada, H.K.; Robin, M.A.; Boopathi, E.; Biswas, G.; Fang, J.K.; Nebert, D.W.; Avadhani, N.G. Role of protein kinase C-mediated protein phosphorylation in mitochondrial translocation of mouse CYP1A1, which contains a noncanonical targeting signal. J. Biol. Chem., 2006, 281, 30834-47.
60. Bhagwat, S.V.; Mullick, J.; Raza, H.; Avadhani, N.G. Constitutive and inducible cytochromes P450 in rat lung mitochondria: xenobiotic induction, relative abundance, and catalytic properties. Toxicol. Appl. Pharmacol.,1999, 156, 231-40.
61. Robin, M.A.; Anandatheerthavarada, H.K.; Biswas, G.; Sepuri, N.B.; Gordon, D.M.; Pain, D.; Avadhani, N.G. Bimodal targeting of microsomal CYP2E1 to mitochondria through activation of an N-terminal chimeric signal by cAMP-mediated phosphorylation. J. Biol. Chem., 2002, 277, 40583-93.
62. Sangar, M.C.; Anandatheerthavarada, H.K.; Martin, M.V.; Guengerich, F.P.; Avadhani, N.G. Identification of genetic variants of human cytochrome P450 2D6 with impaired mitochondrial targeting. Mol. Genet. Metab., 2010, 99, 90-7.
63. High, S.; Dobberstein, B. The signal sequence interacts with the methionine-rich domain of the 54-kD protein of signal recognition particle. J. Cell Biol., 1991, 113, 229-33.
64. Oliver, J.; Jungnickel, B.; Gorlich, D.; Rapoport, T.; High, S. The Sec61 complex is essential for the insertion of proteins into the membrane of the endoplasmic reticulum. FEBS Lett., 1995, 362, 126-30.
65. Bar-Nun, S.; Kreibich, G.; Adesnik, M.; Alterman, L.; Negishi, M.; Sabatini, D.D. Synthesis and insertion of cytochrome P-450 into endoplasmic reticulum membranes. Proc. Natl. Acad. Sci. U. S. A., 1980, 77, 965-9.
66. Monier, S.; Van Luc, P.; Kreibich, G.; Sabatini, D.D.; Adesnik, M. Signals for the incorporation and orientation of cytochrome P450 in the endoplasmic reticulum membrane. J. Cell Biol., 1988, 107, 457-70.
67. Sakaguchi, M.; Tomiyoshi, R.; Kuroiwa, T.; Mihara, K.; Omura, T. Functions of signal and signal-anchor sequences are determined by the balance between the hydrophobic segment and the N-terminal charge. Proc. Natl. Acad. Sci. U. S. A., 1992, 89, 16-9.
68. Szczesna-Skorupa, E.; Kemper, B. Endoplasmic reticulum retention determinants in the transmembrane and linker domains of cytochrome P450 2C1. J. Biol. Chem., 2000, 275, 19409-15.
69. Szczesna-Skorupa, E.; Kemper, B. The juxtamembrane sequence of cytochrome P-450 2C1 contains an endoplasmic reticulum retention signal. J. Biol. Chem., 2001, 276, 45009-14.
70. Anandatheerthavarada, H.K.; Sepuri, N.B.V.; Avadhani, N.G. Mitochondrial targeting of cytochrome P450 proteins containing NH2-terminal chimeric signals involves an unusual TOM20/TOM22 bypass mechanism. J. Biol. Chem., 2009, 284, 17352-17363.
71. Anandatheerthavarada, H.K.; Addya, S.; Dwivedi, R.S.; Biswas, G.; Mullick, J.; Avadhani, N.G. Localization of Multiple Forms of Inducible Cytochromes P450 in Rat Liver Mitochondria: Immunological Characteristics and Patterns of Xenobiotic Substrate Metabolism. Arch. Biochem. Biophys., 1997, 339, 136-150.
72. Robin, M.-A.; Anandatheerthavarada, H.K.; Fang, J.-K.; Cudic, M.; Otvos, L.; Avadhani, N.G. Mitochondrial targeted cytochrome P450 2E1 (P450 MT5) contains an intact N terminus and requires mitochondrial specific electron transfer proteins for activity. J. Biol. Chem., 2001, 276, 24680-24689.
73. Genter, M.B.; Clay, C.D.; Dalton, T.P.; Dong, H.; Nebert, D.W.; Shertzer, H.G. Comparison of mouse hepatic mitochondrial versus microsomal cytochromes P450 following TCDD treatment. Biochem. Biophys. Res. Commun., 2006, 342, 1375-81.
74. Sangar, M.C.; Anandatheerthavarada, H.K.; Tang, W.; Prabu, S.K.; Martin, M.V.; Dostalek, M.; Guengerich, F.P.; Avadhani, N.G. Human liver mitochondrial cytochrome P450 2D6 - individual variations and implications in drug metabolism. FEBS J., 2009, 276, 3440-53.
75. Sepuri, N.B.; Yadav, S.; Anandatheerthavarada, H.K.; Avadhani, N.G. Mitochondrial targeting of intact CYP2B1 and CYP2E1 and N-terminal truncated CYP1A1 proteins in Saccharomyces cerevisiae - role of protein kinase A in the mitochondrial targeting of CYP2E1. FEBS J., 2007, 274, 4615-30.
76. Huang, L.J.; Wang, L.; Ma, Y.; Durick, K.; Perkins, G.; Deerinck, T.J.; Ellisman, M.H.; Taylor, S.S. NH2-Terminal targeting motifs direct dual specificity A-kinase-anchoring protein 1 (D-AKAP1) to either mitochondria or endoplasmic reticulum. J. Cell Biol., 1999, 145, 951-9.
77. Raza, H.; Robin, M.A.; Fang, J.K.; Avadhani, N.G. Multiple isoforms of mitochondrial glutathione S-transferases and their differential induction under oxidative stress. Biochem. J., 2002, 366, 45-55.
78. Robin, M.A.; Prabu, S.K.; Raza, H.; Anandatheerthavarada, H.K.; Avadhani, N.G. Phosphorylation enhances mitochondrial targeting of GSTA4-4 through increased affinity for binding to cytoplasmic Hsp70. J. Biol. Chem., 2003, 278, 18960-70.
79. Colombo, S.; Longhi, R.; Alcaro, S.; Ortuso, F.; Sprocati, T.; Flora, A.; Borgese, N. N-myristoylation determines dual targeting of mammalian NADH-cytochrome b5 reductase to ER and mitochondrial outer membranes by a mechanism of kinetic partitioning. J. Cell Biol., 2005, 168, 735-45.
80. Wang, H.G.; Rapp, U.R.; Reed, J.C. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell, 1996, 87, 629-38.
81. Majumder, P.K.; Pandey, P.; Sun, X.; Cheng, K.; Datta, R.; Saxena, S.; Kharbanda, S.; Kufe, D. Mitochondrial translocation of protein kinase C delta in phorbol ester-induced cytochrome c release and apoptosis. J. Biol. Chem., 2000, 275, 21793-6.
82. Wegrzyn, J.; Potla, R.; Chwae, Y.J.; Sepuri, N.B.; Zhang, Q.; Koeck, T.; Derecka, M.; Szczepanek, K.; Szelag, M.; Gornicka, A. and others. Function of mitochondrial Stat3 in cellular respiration. Science, 2009, 323, 793-7.
83. Boopathi, E.; Srinivasan, S.; Fang, J.K.; Avadhani, N.G. Bimodal protein targeting through activation of cryptic mitochondrial targeting signals by an inducible cytosolic endoprotease. Mol. Cell, 2008, 32, 32-42.
84. Dasari, V.R.; Anandatheerthavarada, H.K.; Robin, M.-A.; Boopathi, E.; Biswas, G.; Fang, J.-K.; Nebert, D.W.; Avadhani, N.G. Role of protein kinase C-mediated protein phosphorylation in mitochondrial translocation of mouse CYP1A1, which contains a non-canonical targeting signal. J. Biol. Chem., 2006, 281, 30834-30847.
85. Bansal, S.; Leu, A.N.; Gonzalez, F.J.; Guengerich, F.P.; Chowdhury, A.R.; Anandatheerthavarada, H.K.; Avadhani, N.G. Mitochondrial Targeting of Cytochrome P450 (CYP) 1B1 and Its Role in Polycyclic Aromatic Hydrocarbon-induced Mitochondrial Dysfunction. J. Biol. Chem., 2014, 289, 9936-9951.
86. Anandatheerthavarada, H.K.; Biswas, G.; Mullick, J.; Sepuri, N.B.V.; Otvos, L.; Pain, D.; Avadhani, N.G. Dual targeting of cytochrome P4502B1 to endoplasmic reticulum and mitochondria involves a novel signal activation by cyclic AMP dependent phosphorylation at Ser128. EMBO J., 1999. 5494-5504.
87. Bansal, S.; Liu, C.-P.; Sepuri, N.B.; Anandatheerthavarada, H.K.; Selvaraj, V.; Hoek, J.; Milne, G.L.; Guengerich, F.P.; Avadhani, N.G. Mitochondria-targeted cytochrome P450 2E1 induces oxidative damage and augments alcohol-mediated oxidative stress. J. Biol. Chem., 2010, 285, 24609-24619.
88. Neve, E.P.; Ingelman-Sundberg, M. Identification and characterization of a mitochondrial targeting signal in rat cytochrome P450 2E1 (CYP2E1). J. Biol. Chem., 2001, 276, 11317-22.
89. Knockaert, L.; Fromenty, B.; Robin, M.A. Mechanisms of mitochondrial targeting of cytochrome P450 2E1: physiopathological role in liver injury and obesity. FEBS J., 2011, 278, 4252-60.
90. Neupert, W.; Herrmann, J.M. Translocation of proteins into mitochondria. Annu. Rev. Biochem., 2007, 76, 723-49.
91. Suzuki, H.; Kadowaki, T.; Maeda, M.; Sasaki, H.; Nabekura, J.; Sakaguchi, M.; Mihara, K. Membrane-embedded C-terminal segment of rat mitochondrial TOM40 constitutes protein-conducting pore with enriched beta-structure. J. Biol. Chem., 2004, 279, 50619-29.
92. Pfanner, N.; Craig, E.A.; Meijer, M. The protein import machinery of the mitochondrial inner membrane. Trends Biochem. Sci., 1994, 19, 368-72.
93. Ryan, K.R.; Jensen, R.E. Protein translocation across mitochondrial membranes: what a long, strange trip it is. Cell, 1995, 83, 517-9.
94. Schneider, H.C.; Berthold, J.; Bauer, M.F.; Dietmeier, K.; Guiard, B.; Brunner, M.; Neupert, W. Mitochondrial Hsp70/MIM44 complex facilitates protein import. Nature, 1994, 371, 768-74.
95. Brix, J.; Dietmeier, K.; Pfanner, N. Differential recognition of preproteins by the purified cytosolic domains of the mitochondrial import receptors Tom20, Tom22, and Tom70. J. Biol. Chem., 1997, 272, 20730-5.
96. Brix, J.; Rudiger, S.; Bukau, B.; Schneider-Mergener, J.; Pfanner, N. Distribution of binding sequences for the mitochondrial import receptors Tom20, Tom22, and Tom70 in a presequence-carrying preprotein and a non-cleavable preprotein. J. Biol. Chem., 1999, 274, 16522-30.
97. Meisinger, C.; Ryan, M.T.; Hill, K.; Model, K.; Lim, J.H.; Sickmann, A.; Muller, H.; Meyer, H.E.; Wagner, R.; Pfanner, N. Protein import channel of the outer mitochondrial membrane: a highly stable Tom40-Tom22 core structure differentially interacts with preproteins, small tom proteins, and import receptors. Mol. Cell. Biol., 2001, 21, 2337-48.
98. Van Wilpe, S.; Ryan, M.T.; Hill, K.; Maarse, A.C.; Meisinger, C.; Brix, J.; Dekker, P.J.; Moczko, M.; Wagner, R.; Meijer, M. and others. Tom22 is a multifunctional organizer of the mitochondrial preprotein translocase. Nature, 1999, 401, 485-9.
99. Ellis, R.J. Molecular chaperones: Plugging the transport gap. Nature, 2003, 421, 801-2.
100. Ren, J.; Bharti, A.; Raina, D.; Chen, W.; Ahmad, R.; Kufe, D. MUC1 oncoprotein is targeted to mitochondria by heregulininduced activation of c-Src and the molecular chaperone HSP90. Oncogene, 2006, 25, 20-31.
101. Voos, W.; Rottgers, K. Molecular chaperones as essential mediators of mitochondrial biogenesis. Biochim. Biophys. Acta, 2002, 1592, 51-62.
102. Voos, W. A new connection: chaperones meet a mitochondrial receptor. Mol. Cell, 2003, 11, 1-3.
103. Beddoe, T.; Lithgow, T. Delivery of nascent polypeptides to the mitochondrial surface. Biochim. Biophys. Acta, 2002, 1592, 35-9.
104. Deshaies, R.J.; Koch, B.D.; Schekman, R. The role of stress proteins in membrane biogenesis. Trends Biochem. Sci.,1988, 13, 384-8.
105. Hartl, F.U.; Hayer-Hartl, M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science, 2002, 295, 1852-8.
106. Murakami, H.; Pain, D.; Blobel, G. 70-kD heat shock-related protein is one of at least two distinct cytosolic factors stimulating protein import into mitochondria. J. Cell Biol., 1988, 107, 2051-7.
107. Sakaki, T.; Kominami, S.; Hayashi, K.; Akiyoshi-Shibata, M.; Yabusaki, Y. Molecular engineering study on electron transfer from NADPH-P450 reductase to rat mitochondrial P450c27 in yeast microsomes. J. Biol. Chem., 1996, 271, 26209-13.
108. Anandatheerthavarada, H.K.; Addya, S.; Mullick, J.; Avadhani, N.G. Interaction of adrenodoxin with P4501A1 and its truncated form P450MT2 through different domains: differential modulation of enzyme activities. Biochemistry, 1998, 37, 1150-60.
109. Mootha, V.K.; Bunkenborg, J.; Olsen, J.V.; Hjerrild, M.; Wisniewski, J.R.; Stahl, E.; Bolouri, M.S.; Ray, H.N.; Sihag, S.; Kamal, M. and others. Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria. Cell, 2003, 115, 629-40.
110. Prokisch, H.; Andreoli, C.; Ahting, U.; Heiss, K.; Ruepp, A.; Scharfe, C.; Meitinger, T. MitoP2: the mitochondrial proteome database - now including mouse data. Nucleic Acids Res., 2006, 34, D705-11.
111. Prokisch, H.; Ahting, U. MitoP2, an integrated database for mitochondrial proteins. Methods Mol. Biol., 2007, 372, 573-86.
112. Bai, J.; Cederbaum, A.I. Cycloheximide protects HepG2 cells from serum withdrawal-induced apoptosis by decreasing p53 and phosphorylated p53 levels. J. Pharmacol. Exp. Ther., 2006, 319, 1435-43.
113. Lieber, C.S.; Cao, Q.; DeCarli, L.M.; Leo, M.A.; Mak, K.M.; Ponomarenko, A.; Ren, C.; Wang, X. Role of medium-chain triglycerides in the alcohol-mediated cytochrome P450 2E1 induction of mitochondria. Alcohol. Clin. Exp. Res., 2007, 31, 1660-8.
114. Moon, K.H.; Hood, B.L.; Kim, B.J.; Hardwick, J.P.; Conrads, T.P.; Veenstra, T.D.; Song, B.J. Inactivation of oxidized and Snitrosylated mitochondrial proteins in alcoholic fatty liver of rats. Hepatology, 2006, 44, 1218-30.
115. Neve, E.P.; Ingelman-Sundberg, M. A soluble NH(2)-terminally truncated catalytically active form of rat cytochrome P450 2E1 targeted to liver mitochondria(1). FEBS Lett., 1999, 460, 309-14.
116. Dong, H.; Dalton, T.P.; Miller, M.L.; Chen, Y.; Uno, S.; Shi, Z.; Shertzer, H.G.; Bansal, S.; Avadhani, N.G.; Nebert, D.W. Knock-in mouse lines expressing either mitochondrial or microsomal CYP1A1: differing responses to dietary benzo[a]pyrene as proof of principle. Mol. Pharmacol., 2009, 75, 555-67.
117. Mari, M.; Wu, D.; Nieto, N.; Cederbaum, A.I. CYP2E1-dependent toxicity and up-regulation of antioxidant genes. J. Biomed. Sci., 2001, 8, 52-8.
118. Leclercq, I.A.; Farrell, G.C.; Field, J.; Bell, D.R.; Gonzalez, F.J.; Robertson, G.R. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J. Clin. Invest., 2000, 105, 1067-75.
119. Lieber, C.S. Cytochrome P-4502E1: its physiological and pathological role. Physiol. Rev., 1997, 77, 517-44.
120. Caro, A.A.; Evans, K.L.; Cederbaum, A.I. CYP2E1 overexpression inhibits microsomal Ca2+-ATPase activity in HepG2 cells. Toxicology, 2009, 255, 171-6.
121. Cederbaum, A.I.; Wu, D.; Mari, M.; Bai, J. CYP2E1-dependent toxicity and oxidative stress in HepG2 cells. Free Radic. Biol. Med., 2001, 31, 1539-43.
122. Liebler, D.C.; Guengerich, F.P. Elucidating mechanisms of druginduced toxicity. Nat. Rev. Drug Discov., 2005, 4, 410-20.
123. Mitchell, J.R.; Jollow, D.J.; Potter, W.Z.; Gillette, J.R.; Brodie, B.B. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J. Pharmacol. Exp. Ther., 1973, 187, 211-7.
124. Patten, C.J.; Thomas, P.E.; Guy, R.L.; Lee, M.; Gonzalez, F.J.; Guengerich, F.P.; Yang, C.S. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem. Res. Toxicol., 1993, 6, 511-8.
125. Thummel, K.E.; Lee, C.A.; Kunze, K.L.; Nelson, S.D.; Slattery, J.T. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem. Pharmacol., 1993, 45, 1563-9.
126. Chen, W.; Koenigs, L.L.; Thompson, S.J.; Peter, R.M.; Rettie, A.E.; Trager, W.F.; Nelson, S.D. Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6. Chem. Res. Toxicol., 1998, 11, 295-301.
127. Nelson, S.D. Molecular mechanisms of the hepatotoxicity caused by acetaminophen. Semin. Liver Dis., 1990, 10, 267-78.
128. Weis, M.; Kass, G.E.; Orrenius, S.; Moldeus, P. N-acetyl-pbenzoquinone imine induces Ca2+ release from mitochondria by stimulating pyridine nucleotide hydrolysis. J. Biol. Chem., 1992, 267, 804-9.
129. Ray, S.D.; Kamendulis, L.M.; Gurule, M.W.; Yorkin, R.D.; Corcoran, G.B. Ca2+ antagonists inhibit DNA fragmentation and toxic cell death induced by acetaminophen. FASEB J., 1993, 7, 453-63.
130. Donnelly, P.J.; Walker, R.M.; Racz, W.J. Inhibition of mitochondrial respiration in vivo is an early event in acetaminophen-induced hepatotoxicity. Arch. Toxicol., 1994, 68, 110-8.
131. Salas, V.M.; Corcoran, G.B. Calcium-dependent DNA damage and adenosine 3′, 5′-cyclic monophosphate-independent glycogen phosphorylase activation in an in vitro model of acetaminophen-induced liver injury. Hepatology, 1997, 25, 1432-1438.
132. Das, J.; Ghosh, J.; Manna, P.; Sil, P.C. Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic. Res., 2010, 44, 340-55.
133. Das, J.; Ghosh, J.; Manna, P.; Sil, P.C. Taurine protects acetaminophen-induced oxidative damage in mice kidney through APAP urinary excretion and CYP2E1 inactivation. Toxicology, 2010, 269, 24-34.
134. Ghosh, J.; Das, J.; Manna, P.; Sil, P.C. Arjunolic acid, a triterpenoid saponin, prevents acetaminophen (APAP)-induced liver and hepatocyte injury via the inhibition of APAP bioactivation and JNK-mediated mitochondrial protection. Free Radical Biol. Med., 2010, 48, 535-553.
135. Ghosh, J.; Das, J.; Manna, P.; Sil, P.C. Acetaminophen induced renal injury via oxidative stress and TNF-alpha production: therapeutic potential of arjunolic acid. Toxicology, 2010, 268, 8-18.
136. Satoh, T. Genetic polymorphism in drug metabolism and toxicity: Linking animal research and risk assessment in man. AATEX, 2007, 14, 443-445.
137. Tucker, G.T. Clinical implications of genetic polymorphism in drug metabolism. J. Pharm. Pharmacol., 1994, 46 Suppl 1, 417-24.
138. Meyer, U.A. The molecular basis of genetic polymorphisms of drug metabolism. J. Pharm. Pharmacol., 1994, 46 Suppl 1, 409-15.
139. Smith, G.; Stubbins, M.J.; Harries, L.W.; Wolf, C.R. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica, 1998, 28, 1129-65.
140. Ma, Q.; Lu, A.Y. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol. Rev.,2011, 63, 437-59.
141. Lu, A.Y. Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety. Drug Metab. Dispos., 1998, 26, 1217-22.
142. Meyer, U.A. Pharmacogenetics and adverse drug reactions. Lancet, 2000, 356, 1667-71.
143. Evans, W.E.; McLeod, H.L. Pharmacogenomics - drug disposition, drug targets, and side effects. N. Engl. J. Med., 2003, 348, 538-49.
144. Weinshilboum, R. Inheritance and drug response. N. Engl. J. Med.,2003, 348, 529-37.
145. Evans, W.E.; Relling, M.V. Moving towards individualized medicine with pharmacogenomics. Nature, 2004, 429, 464-8.
146. Eichelbaum, M.; Ingelman-Sundberg, M.; Evans, W.E. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. ,2006, 57, 119-37.
147. Lin, J.H. Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy. Curr. Drug Metab., 2007, 8, 109-36.
148. Lu, A.Y.; Ma, Q. Pharmacogenetics, Pharmacogenomics, and Individualized Medicine. Pharmacol. Rev., 2011, 63, 437-59.
149. Topol, E.J.; Schork, N.J. Catapulting clopidogrel pharmacogenomics forward. Nat. Med., 2011, 17, 40-1.
150. Jin, Y.; Desta, Z.; Stearns, V.; Ward, B.; Ho, H.; Lee, K.H.; Skaar, T.; Storniolo, A.M.; Li, L.; Araba, A. and others. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst., 2005, 97, 30-9.
151. Masubuchi, Y.; Horie, T. Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs. Crit. Rev. Toxicol., 2007, 37, 389-412.
152. Rando, R.R. Mechanism-based enzyme inactivators. Pharmacol. Rev., 1984, 36, 111-42.
153. Silverman, R.B. Mechanism-based enzyme inactivation: chemistry and enzymology. CRC press Boca Raton, FL:; 1988.
154. Correia, M.A.; de Montellano, P.R.O. Inhibition of cytochrome P450 enzymes. Cytochrome P450: Springer; 2005. p 247-322.
155. Halpert, J.R. Structural basis of selective cytochrome P450 inhibition. Annu. Rev. Pharmacol. Toxicol., 1995, 35, 29-53.
156. Kent, U.M.; Juschyshyn, M.I.; Hollenberg, P.F. Mechanism-based inactivators as probes of cytochrome P450 structure and function. Curr. Drug Metab., 2001, 2, 215-43.
157. Murray, M. Mechanisms of the inhibition of cytochrome P-450-mediated drug oxidation by therapeutic agents. Drug Metab. Rev., 1987, 18, 55-81.
158. Murray, M. Drug-mediated inactivation of cytochrome P450. Clin. Exp. Pharmacol. Physiol., 1997, 24, 465-70.
159. Murray, M.; Reidy, G.F. Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol. Rev., 1990, 42, 85-101.
160. Oritz de Montellano, P.R.; Correia, M.A. Suicidal destruction of cytochrome P-450 during oxidative drug metabolism. Annu. Rev. Pharmacol. Toxicol., 1983, 23, 481-503.
161. Zhou, S.; Chan, E.; Lim, L.Y.; Boelsterli, U.A.; Li, S.C.; Wang, J.; Zhang, Q.; Huang, M.; Xu, A. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr. Drug Metab., 2004, 5, 415-42.
162. Zhou, S.; Yung Chan, S.; Cher Goh, B.; Chan, E.; Duan, W.; Huang, M.; McLeod, H.L. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet., 2005, 44, 279-304.
163. Kunze, K.L.; Trager, W.F. Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol., 1993, 6, 649-56.
164. Tassaneeyakul, W.; Birkett, D.J.; Veronese, M.E.; McManus, M.E.; Tukey, R.H.; Miners, J.O. Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromes P450 1A1 and 1A2. Pharmacogenetics, 1994, 4, 281-4.
165. Bourrie, M.; Meunier, V.; Berger, Y.; Fabre, G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther., 1996, 277, 321-32.
166. Chang, T.K.; Gonzalez, F.J.; Waxman, D.J. Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch. Biochem. Biophys., 1994, 311, 437-42.
167. Eagling, V.A.; Tjia, J.F.; Back, D.J. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br. J. Clin. Pharmacol., 1998, 45, 107-14.
168. Ekins, S.; VandenBranden, M.; Ring, B.J.; Wrighton, S.A. Examination of purported probes of human CYP2B6. Pharmacogenetics, 1997, 7, 165-79.
169. Newton, D.J.; Wang, R.W.; Lu, A.Y. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos., 1995, 23, 154-8.
170. Ono, S.; Hatanaka, T.; Hotta, H.; Satoh, T.; Gonzalez, F.; Tsutsui, M. Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica, 1996, 26, 681-693.
171. Sai, Y.; Dai, R.; Yang, T.J.; Krausz, K.W.; Gonzalez, F.J.; Gelboin, H.V.; Shou, M. Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica, 2000, 30, 327-43.
172. DeVane, C.L.; Markowitz, J.S.; Hardesty, S.J.; Mundy, S.; Gill, H.S. Fluvoxamine-induced theophylline toxicity. Am. J. Psychiatry, 1997, 154, 1317-8.
173. van den Brekel, A.M.; Harrington, L. Toxic effects of theophylline caused by fluvoxamine. CMAJ, 1994, 151, 1289-90.
174. Anderson, J.R.; Nawarskas, J.J. Cardiovascular drug-drug interactions. Cardiol. Clin., 2001, 19, 215-34.
175. Patsalos, P.N.; Froscher, W.; Pisani, F.; van Rijn, C.M. The importance of drug interactions in epilepsy therapy. Epilepsia, 2002, 43, 365-85.
176. Spina, E.; Pisani, F.; Perucca, E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin. Pharmacokinet., 1996, 31, 198-214.
177. Awad, J.A.; Horn, J.L.; Roberts, L.J., 2nd; Franks, J.J. Demonstration of halothane-induced hepatic lipid peroxidation in rats by quantification of F2-isoprostanes. Anesthesiology, 1996, 84, 910-6.
178. Minoda, Y.; Kharasch, E.D. Halothane-dependent lipid peroxidation in human liver microsomes is catalyzed by cytochrome P4502A6 (CYP2A6). Anesthesiology, 2001, 95, 509-14.
179. Spracklin, D.K.; Thummel, K.E.; Kharasch, E.D. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. Drug Metab. Dispos., 1996, 24, 976-83.
180. Krieter, P.A.; van Dyke, R.A. Cytochrome P-450 and halothane metabolism. Decrease in rat liver microsomal P-450 in vitro. Chem. Biol. Interact., 1983, 44, 219-35.
181. Baker, M.T.; Vasquez, M.T.; Chiang, C.K. Evidence for the stability and cytochrome P450 specificity of the phenobarbital-induced reductive halothane-cytochrome P450 complex formed in rat hepatic microsomes. Biochem. Pharmacol., 1991, 41, 1691-9.
182. Manno, M.; Cazzaro, S.; Rezzadore, M. The mechanism of the suicidal reductive inactivation of microsomal cytochrome P-450 by halothane. Arch. Toxicol., 1991, 65, 191-8.
183. Manno, M.; Ferrara, R.; Cazzaro, S.; Rigotti, P.; Ancona, E. Suicidal inactivation of human cytochrome P-450 by carbon tetrachloride and halothane in vitro. Pharmacol. Toxicol., 1992, 70, 13-8.
184. Safirstein, R.; Winston, J.; Goldstein, M.; Moel, D.; Dikman, S.; Guttenplan, J. Cisplatin nephrotoxicity. Am. J. Kidney Dis., 1986, 8, 356-67.
185. Screnci, D.; McKeage, M.J. Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. J. Inorg. Biochem., 1999, 77, 105-10.
186. von Richter, O.; Greiner, B.; Fromm, M.F.; Fraser, R.; Omari, T.; Barclay, M.L.; Dent, J.; Somogyi, A.A.; Eichelbaum, M. Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clin. Pharmacol. Ther., 2001, 70, 217-27.
187. Glaeser, H.; Drescher, S.; Hofmann, U.; Heinkele, G.; Somogyi, A.A.; Eichelbaum, M.; Fromm, M.F. Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans. Clin. Pharmacol. Ther., 2004, 76, 230-8.
188. Obach, R.S.; Zhang, Q.Y.; Dunbar, D.; Kaminsky, L.S. Metabolic characterization of the major human small intestinal cytochrome p450s. Drug Metab. Dispos., 2001, 29, 347-52.
189. Thorn, M.; Finnstrom, N.; Lundgren, S.; Rane, A.; Loof, L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br. J. Clin. Pharmacol., 2005, 60, 54-60.
190. Nebert, D.W.; Russell, D.W. Clinical importance of the cytochromes P450. Lancet, 2002, 360, 1155-62.
191. Guengerich, F.P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol., 1999, 39, 1-17.
192. Paine, M.F.; Hart, H.L.; Ludington, S.S.; Haining, R.L.; Rettie, A.E.; Zeldin, D.C. The human intestinal cytochrome P450 "pie". Drug Metab. Dispos., 2006, 34, 880-6.
193. van de Kerkhof, E.G.; Ungell, A.L.; Sjoberg, A.K.; de Jager, M.H.; Hilgendorf, C.; de Graaf, I.A.; Groothuis, G.M. Innovative methods to study human intestinal drug metabolism in vitro: precision-cut slices compared with ussing chamber preparations. Drug Metab. Dispos., 2006, 34, 1893-902.
194. Doherty, M.M.; Charman, W.N. The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin. Pharmacokinet., 2002, 41, 235-53.
195. Wang, H.; LeCluyse, E.L. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin. Pharmacokinet., 2003, 42, 1331-57.
196. Meyer, U.A. Overview of enzymes of drug metabolism. J. Pharmacokinet. Biopharm., 1996, 24, 449-59.
197. Jancova, P.; Anzenbacher, P.; Anzenbacherova, E. Phase II drug metabolizing enzymes. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub., 2010, 154, 103-16.
198. Shelby, M.K.; Cherrington, N.J.; Vansell, N.R.; Klaassen, C.D. Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. Drug Metab. Dispos., 2003, 31, 326-33.
199. Takemoto, K.; Yamazaki, H.; Tanaka, Y.; Nakajima, M.; Yokoi, T. Catalytic activities of cytochrome P450 enzymes and UDPglucuronosyltransferases involved in drug metabolism in rat everted sacs and intestinal microsomes. Xenobiotica, 2003, 33, 43-55.
200. Hoensch, H.; Peters, W.H.; Roelofs, H.M.; Kirch, W. Expression of the glutathione enzyme system of human colon mucosa by localisation, gender and age. Curr. Med. Res. Opin., 2006, 22, 1075-83.
201. Zordoky, B.N.; El-Kadi, A.O. Role of NF-kappaB in the regulation of cytochrome P450 enzymes. Curr. Drug Metab., 2009, 10, 164-78.
202. Zhang, Y.; Benet, L.Z. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet., 2001, 40, 159-68.
203. Mouly, S.; Paine, M.F. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm. Res., 2003, 20, 1595-9.
204. Zimmermann, C.; Gutmann, H.; Hruz, P.; Gutzwiller, J.P.; Beglinger, C.; Drewe, J. Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metab. Dispos., 2005, 33, 219-24.
205. Meier, Y.; Eloranta, J.J.; Darimont, J.; Ismair, M.G.; Hiller, C.; Fried, M.; Kullak-Ublick, G.A.; Vavricka, S.R. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab. Dispos., 2007, 35, 590-4.
206. Gutmann, H.; Hruz, P.; Zimmermann, C.; Beglinger, C.; Drewe, J. Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem. Pharmacol., 2005, 70, 695-9.
207. Englund, G.; Rorsman, F.; Ronnblom, A.; Karlbom, U.; Lazorova, L.; Grasjo, J.; Kindmark, A.; Artursson, P. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm. Sci., 2006, 29, 269-77.
208. Hruz, P.; Zimmermann, C.; Gutmann, H.; Degen, L.; Beuers, U.; Terracciano, L.; Drewe, J.; Beglinger, C. Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis. Gut, 2006, 55, 395-402.
209. Kliewer, S.A. The nuclear pregnane X receptor regulates xenobiotic detoxification. J. Nutr., 2003, 133, 2444S-2447S.
210. Kliewer, S.A.; Goodwin, B.; Willson, T.M. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr. Rev., 2002, 23, 687-702.
211. Lehmann, J.M.; McKee, D.D.; Watson, M.A.; Willson, T.M.; Moore, J.T.; Kliewer, S.A. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest., 1998, 102, 1016-23.
212. Blumberg, B.; Sabbagh, W., Jr.; Juguilon, H.; Bolado, J., Jr.; van Meter, C.M.; Ong, E.S.; Evans, R.M. SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev., 1998, 12, 3195-205.
213. Kliewer, S.A.; Moore, J.T.; Wade, L.; Staudinger, J.L.; Watson, M.A.; Jones, S.A.; McKee, D.D.; Oliver, B.B.; Willson, T.M.; Zetterstrom, R.H. and others. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell, 1998, 92, 73-82.
214. Kliewer, S.A.; Lehmann, J.M.; Milburn, M.V.; Willson, T.M. The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways. Recent Prog. Horm. Res., 1999, 54, 345-67; discussion 367-8.
215. Moore, L.B.; Maglich, J.M.; McKee, D.D.; Wisely, B.; Willson, T.M.; Kliewer, S.A.; Lambert, M.H.; Moore, J.T. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol. Endocrinol., 2002, 16, 977-986.
216. Moore, J.T.; Kliewer, S.A. Use of the nuclear receptor PXR to predict drug interactions. Toxicology ,2000, 153, 1-10.
217. Bertilsson, G.; Heidrich, J.; Svensson, K.; Åsman, M.; Jendeberg, L.; Sydow-Bäckman, M.; Ohlsson, R.; Postlind, H.; Blomquist, P.; Berkenstam, A. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc. Natl. Acad. Sci. U. S .A, 1998, 95, 12208-12213.
218. Nakata, K.; Tanaka, Y.; Nakano, T.; Adachi, T.; Tanaka, H.; Kaminuma, T.; Ishikawa, T. Nuclear receptor-mediated transcriptional regulation in Phase I, II, and III xenobiotic metabolizing systems. Drug Metab. Pharmacokinet., 2006, 21, 437-57.
219. Timsit, Y.E.; Negishi, M. CAR and PXR: the xenobiotic-sensing receptors. Steroids, 2007, 72, 231-46.
220. Matic, M.; Mahns, A.; Tsoli, M.; Corradin, A.; Polly, P.; Robertson, G.R. Pregnane X receptor: promiscuous regulator of detoxification pathways. Int. J. Biochem. Cell Biol. ,2007, 39, 478-83.
221. Pondugula, S.R.; Mani, S. Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response. Cancer Lett., 2013, 328, 1-9.
222. Raynal, C.; Pascussi, J.M.; Leguelinel, G.; Breuker, C.; Kantar, J.; Lallemant, B.; Poujol, S.; Bonnans, C.; Joubert, D.; Hollande, F. and others. Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol. Cancer, 2010, 9, 46.
223. Chen, Y.; Nie, D. Pregnane X receptor and its potential role in drug resistance in cancer treatment. Recent Pat. Anticancer Drug Discov., 2009, 4, 19-27.
224. Gupta, D.; Venkatesh, M.; Wang, H.; Kim, S.; Sinz, M.; Goldberg, G.L.; Whitney, K.; Longley, C.; Mani, S. Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer. Clin. Cancer. Res., 2008, 14, 5332-40.
225. Xu, C.; Li, C.Y.; Kong, A.N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res., 2005, 28, 249-68.
226. Scott, M.J.; Liu, S.; Shapiro, R.A.; Vodovotz, Y.; Billiar, T.R. Endotoxin uptake in mouse liver is blocked by endotoxin pretreatment through a suppressor of cytokine signaling-1-dependent mechanism. Hepatology, 2009, 49, 1695-708.
227. Barker, C.W.; Fagan, J.B.; Pasco, D.S. Interleukin-1 beta suppresses the induction of P4501A1 and P4501A2 mRNAs in isolated hepatocytes. J. Biol. Chem., 1992, 267, 8050-5.
228. Muntane-Relat, J.; Ourlin, J.C.; Domergue, J.; Maurel, P. Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology, 1995, 22, 1143-53.
229. Morris, S.M., Jr.; Billiar, T.R. New insights into the regulation of inducible nitric oxide synthesis. Am. J. Physiol., 1994, 266, E829-39.
230. Abdulla, D.; Goralski, K.B.; Del Busto Cano, E.G.; Renton, K.W. The signal transduction pathways involved in hepatic cytochrome P450 regulation in the rat during a lipopolysaccharide-induced model of central nervous system inflammation. Drug Metab. Dispos., 2005, 33, 1521-31.
231. Gu, X.; Ke, S.; Liu, D.; Sheng, T.; Thomas, P.E.; Rabson, A.B.; Gallo, M.A.; Xie, W.; Tian, Y. Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J. Biol. Chem., 2006, 281, 17882-9.
232. Adam-Stitah, S.; Penna, L.; Chambon, P.; Rochette-Egly, C. Hyperphosphorylation of the retinoid X receptor alpha by activated c-Jun NH2-terminal kinases. J. Biol. Chem., 1999, 274, 18932-41.
233. Yu, R.; Lei, W.; Mandlekar, S.; Weber, M.J.; Der, C.J.; Wu, J.; Kong, A.N. Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals. J. Biol. Chem., 1999, 274, 27545-52.
234. Kalgutkar, A.S.; Gardner, I.; Obach, R.S.; Shaffer, C.L.; Callegari, E.; Henne, K.R.; Mutlib, A.E.; Dalvie, D.K.; Lee, J.S.; Nakai, Y. and others. A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab., 2005, 6, 161-225.
235. Masubuchi, N.; Makino, C.; Murayama, N. Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. Chem. Res. Toxicol., 2007, 20, 455-464.
236. Evans, D.C.; Watt, A.P.; Nicoll-Griffith, D.A.; Baillie, T.A. Drugprotein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol., 2004, 17, 3-16.
237. Kalgutkar, A.S.; Obach, R.S.; Maurer, T.S. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drugdrug interactions and idiosyncratic adverse drug reactions. Curr. Drug Metab., 2007, 8, 407-447.
238. Shu, Y.Z.; Johnson, B.M.; Yang, T.J. Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery. AAPS J., 2008, 10, 178-92.
239. Jones, D.R.; Miller, G.P. Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know. Expert Opin. Drug Metab. Toxicol., 2011, 7, 857-74.
240. Hermans, J.J.; Thijssen, H.H. Properties and stereoselectivity of carbonyl reductases involved in the ketone reduction of warfarin and analogues. Adv. Exp. Med. Biol., 1993, 328, 351-60.
241. Schmidt, D.; Elger, C.E. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav., 2004, 5, 627-35.
242. Malatkova, P.; Wsol, V. Carbonyl reduction pathways in drug metabolism. Drug Metab. Rev., 2014, 46, 96-123.
243. Manns, M.P.; Markova, A.A.; Calle Serrano, B.; Cornberg, M. Phase III results of Boceprevir in treatment naive patients with chronic hepatitis C genotype 1. Liver Int., 2012, 32 Suppl 1, 27-31.
244. Ghosal, A.; Yuan, Y.; Tong, W.; Su, A.D.; Gu, C.; Chowdhury, S.K.; Kishnani, N.S.; Alton, K.B. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab. Dispos., 2011, 39, 510-21.
245. Chowdhury, G.; Shibata, N.; Yamazaki, H.; Guengerich, F.P. Human cytochrome P450 oxidation of 5-hydroxythalidomide and pomalidomide, an amino analogue of thalidomide. Chem. Res. Toxicol., 2014, 27, 147-56.
246. Nishigaki, R.; Totsuka, Y.; Takamura-Enya, T.; Sugimura, T.; Wakabayashi, K. Identification of cytochrome P-450s involved in the formation of APNH from norharman with aniline. Mutat. Res., 2004, 562, 19-25.
247. Ingelman-Sundberg, M. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat. Res., 2001, 482, 11-9.
248. Knowles, S.R.; Uetrecht, J.; Shear, N.H. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet, 2000, 356, 1587-91.
249. Uetrecht, J.P. New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system. Chem. Res. Toxicol., 1999, 12, 387-95.
250. Naisbitt, D.J. Drug hypersensitivity reactions in skin: understanding mechanisms and the development of diagnostic and predictive tests. Toxicology, 2004, 194, 179-96.
251. Pichler, W.J.; Yawalkar, N.; Britschgi, M.; Depta, J.; Strasser, I.; Schmid, S.; Kuechler, P.; Naisbitt, D. Cellular and molecular pathophysiology of cutaneous drug reactions. Am. J. Clin. Dermatol., 2002, 3, 229-38.
252. Nassif, A.; Bensussan, A.; Boumsell, L.; Deniaud, A.; Moslehi, H.; Wolkenstein, P.; Bagot, M.; Roujeau, J.C. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J. Allergy Clin. Immunol., 2004, 114, 1209-15.
253. Nassif, A.; Bensussan, A.; Dorothee, G.; Mami-Chouaib, F.; Bachot, N.; Bagot, M.; Boumsell, L.; Roujeau, J.C. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J. Invest. Dermatol., 2002, 118, 728-33.
254. Cheng, C.Y.; Su, S.C.; Chen, C.H.; Chen, W.L.; Deng, S.T.; Chung, W.H. HLA Associations and Clinical Implications in TCell Mediated Drug Hypersensitivity Reactions: An Updated Review. J. Immunol. Res., 2014, 2014, 565320.
255. Naisbitt, D.J.; Britschgi, M.; Wong, G.; Farrell, J.; Depta, J.P.; Chadwick, D.W.; Pichler, W.J.; Pirmohamed, M.; Park, B.K. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol. Pharmacol., 2003, 63, 732-41.
256. Naisbitt, D.J.; Farrell, J.; Chamberlain, P.J.; Hopkins, J.E.; Berry, N.G.; Pirmohamed, M.; Park, B.K. Characterization of the T-cell response in a patient with phenindione hypersensitivity. J. Pharmacol. Exp. Ther., 2005, 313, 1058-65.
257. Naisbitt, D.J.; Farrell, J.; Wong, G.; Depta, J.P.; Dodd, C.C.; Hopkins, J.E.; Gibney, C.A.; Chadwick, D.W.; Pichler, W.J.; Pirmohamed, M. and others. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J. Allergy Clin. Immunol.,2003, 111, 1393-403.
258. von Greyerz, S.; Zanni, M.P.; Frutig, K.; Schnyder, B.; Burkhart, C.; Pichler, W.J. Interaction of sulfonamide derivatives with the TCR of sulfamethoxazole-specific human alpha beta+ T cell clones. J. Immunol., 1999, 162, 595-602.
259. Zanni, M.P.; Mauri-Hellweg, D.; Brander, C.; Wendland, T.; Schnyder, B.; Frei, E.; von Greyerz, S.; Bircher, A.; Pichler, W.J. Characterization of lidocaine-specific T cells. J. Immunol., 1997, 158, 1139-48.
260. Schnyder, B.; Frutig, K.; Mauri-Hellweg, D.; Limat, A.; Yawalkar, N.; Pichler, W.J. T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazol-induced skin reaction. Clin. Exp. Allergy, 1998, 28, 1412-7.
261. Pirmohamed, M.; Naisbitt, D.J.; Gordon, F.; Park, B.K. The danger hypothesis - potential role in idiosyncratic drug reactions. Toxicology, 2002, 181-182, 55-63.
262. Mortensen, E.S.; Fenton, K.A.; Rekvig, O.P. Lupus nephritis: the central role of nucleosomes revealed. Am. J. Pathol., 2008, 172, 275-83.
263. Knowles, S.R.; Shapiro, L.; Shear, N.H. Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Arch. Dermatol., 1996, 132, 934-9.
264. Roujeau, J.C.; Stern, R.S. Severe adverse cutaneous reactions to drugs. N. Engl. J. Med., 1994, 331, 1272-85.
265. Schlienger, R.G.; Knowles, S.R.; Shear, N.H. Lamotrigineassociated anticonvulsant hypersensitivity syndrome. Neurology, 1998, 51, 1172-5.
266. Shear, N.H.; Spielberg, S.P. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J. Clin. Invest., 1988, 82, 1826-32.
267. Gupta, A.; Eggo, M.C.; Uetrecht, J.P.; Cribb, A.E.; Daneman, D.; Rieder, M.J.; Shear, N.H.; Cannon, M.; Spielberg, S.P. Druginduced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin. Pharmacol. Ther., 1992, 51, 56-67.
268. Roychowdhury, S.; Svensson, C.K. Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin. AAPS J., 2005, 7, E834-46.
269. Stricker, B.H.; Van den Broek, J.W.; Keuning, J.; Eberhardt, W.; Houben, H.G.; Johnson, M.; Blok, A.P. Cholestatic hepatitis due to antibacterial combination of amoxicillin and clavulanic acid (augmentin). Dig. Dis. Sci., 1989, 34, 1576-80.
270. Lowery, N.; Kearns, G.L.; Young, R.A.; Wheeler, J.G. Serum sickness-like reactions associated with cefprozil therapy. J. Pediatr., 1994, 125, 325-8.
271. Su, S.C.; Chung, W.H.; Hung, S.I. Digging up the human genome: current progress in deciphering adverse drug reactions. Biomed. Res. Int., 2014, 2014, 824343.
272. Bozina, N.; Bradamante, V.; Lovric, M. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh. Hig. Rada Toksikol., 2009, 60, 217-42.
273. Wang, B.; Wang, J.; Huang, S.Q.; Su, H.H.; Zhou, S.F. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr. Drug Metab., 2009, 10, 781-834.
274. Sim, S.C.; Kacevska, M.; Ingelman-Sundberg, M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J., 2013, 13, 1-11.
275. Hulot, J.S.; Bura, A.; Villard, E.; Azizi, M.; Remones, V.; Goyenvalle, C.; Aiach, M.; Lechat, P.; Gaussem, P. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood, 2006, 108, 2244-7.
276. Mrazek, D.A.; Biernacka, J.M.; O'Kane, D.J.; Black, J.L.; Cunningham, J.M.; Drews, M.S.; Snyder, K.A.; Stevens, S.R.; Rush, A.J.; Weinshilboum, R.M. CYP2C19 variation and citalopram response. Pharmacogenet. Genomics, 2011, 21, 1-9.
277. Sim, S.C.; Nordin, L.; Andersson, T.M.; Virding, S.; Olsson, M.; Pedersen, N.L.; Ingelman-Sundberg, M. Association between CYP2C19 polymorphism and depressive symptoms. Am. J. Med. Genet. B Neuropsychiatr. Genet., 2010, 153B, 1160-6.
278. Innocenti, F.; Ratain, M.J. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics, 2006, 7, 1211-21.
279. Toffoli, G.; Cecchin, E.; Corona, G.; Russo, A.; Buonadonna, A.; D'Andrea, M.; Pasetto, L.M.; Pessa, S.; Errante, D.; De Pangher, V. and others. The role of UGT1A1∗28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol., 2006, 24, 3061-8.
280. Chung, W.H.; Hung, S.I.; Hong, H.S.; Hsih, M.S.; Yang, L.C.; Ho, H.C.; Wu, J.Y.; Chen, Y.T. Medical genetics: a marker for Stevens-Johnson syndrome. Nature, 2004, 428, 486.
281. Chung, W.H.; Hung, S.I.; Yang, J.Y.; Su, S.C.; Huang, S.P.; Wei, C.Y.; Chin, S.W.; Chiou, C.C.; Chu, S.C.; Ho, H.C. and others. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat. Med. ,2008, 14, 1343-50.
282. Hetherington, S.; Hughes, A.R.; Mosteller, M.; Shortino, D.; Baker, K.L.; Spreen, W.; Lai, E.; Davies, K.; Handley, A.; Dow, D.J. and others. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet, 2002, 359, 1121-2.
283. Martin, A.M.; Nolan, D.; James, I.; Cameron, P.; Keller, J.; Moore, C.; Phillips, E.; Christiansen, F.T.; Mallal, S. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1∗0101 and abrogated by low CD4 T-cell counts. AIDS ,2005, 19, 97-9.
284. Chantarangsu, S.; Mushiroda, T.; Mahasirimongkol, S.; Kiertiburanakul, S.; Sungkanuparph, S.; Manosuthi, W.; Tantisiriwat, W.; Charoenyingwattana, A.; Sura, T.; Chantratita, W. and others. HLA-B∗3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet. Genomics, 2009, 19, 139-46.
285. Littera, R.; Carcassi, C.; Masala, A.; Piano, P.; Serra, P.; Ortu, F.; Corso, N.; Casula, B.; La Nasa, G.; Contu, L. and others. HLA dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS, 2006, 20, 1621-6.
286. Ciccacci, C.; Di Fusco, D.; Marazzi, M.C.; Zimba, I.; Erba, F.; Novelli, G.; Palombi, L.; Borgiani, P.; Liotta, G. Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study. Eur. J. Clin. Pharmacol., 2013, 69, 1909-16.
287. Zhang, F.R.; Liu, H.; Irwanto, A.; Fu, X.A.; Li, Y.; Yu, G.Q.; Yu, Y.X.; Chen, M.F.; Low, H.Q.; Li, J.H. and others. HLA-B∗13:01 and the dapsone hypersensitivity syndrome. N. Engl. J. Med., 2013, 369, 1620-8.
288. Valko, M.; Rhodes, C.J.; Moncol, J.; Izakovic, M.; Mazur, M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact., 2006, 160, 1-40.
289. Fortini, P.; Pascucci, B.; Parlanti, E.; D'Errico, M.; Simonelli, V.; Dogliotti, E. 8-Oxoguanine DNA damage: at the crossroad of alternative repair pathways. Mutat. Res., 2003, 531, 127-39.
290. Evans, W.E.; Relling, M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 1999, 286, 487-91.
291. Sachse, C.; Brockmoller, J.; Bauer, S.; Roots, I. Functional significance of a C - >A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol., 1999, 47, 445-9.
292. Farrugia, G.; Balzan, R. Oxidative stress and programmed cell death in yeast. Front. Oncol., 2012, 2, 64.
293. Cabiscol, E.; Piulats, E.; Echave, P.; Herrero, E.; Ros, J. Oxidative stress promotes specific protein damage in Saccharomyces cerevisiae. J. Biol. Chem., 2000, 275, 27393-8.
294. Bilinski, T.; Litwinska, J.; Blaszczynski, M.; Bajus, A. Superoxide dismutase deficiency and the toxicity of the products of autooxidation of polyunsaturated fatty acids in yeast. Biochim. Biophys. Acta, 1989, 1001, 102-6.
295. Yakes, F.M.; Van Houten, B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc. Natl. Acad. Sci. U. S. A., 1997, 94, 514-9.
296. Gorsky, L.D.; Koop, D.R.; Coon, M.J. On the stoichiometry of the oxidase and monooxygenase reactions catalyzed by liver microsomal cytochrome P-450. Products of oxygen reduction. J. Biol. Chem., 1984, 259, 6812-7.
297. Kuthan, H.; Ullrich, V. Oxidase and oxygenase function of the microsomal cytochrome P450 monooxygenase system. Eur. J. Biochem., 1982, 126, 583-8.
298. Zhukov, A.A.; Archakov, A.I. Stoichiometry of microsomal oxidation reactions. Distribution of redox-equivalents in monooxygenase and oxidase reactions catalyzed by cytochrome P-450. Biokhimiia, 1985, 50, 1939-52.
299. Zhukov, A.A.; Archakov, A.I. Complete stoichiometry of free NADPH oxidation in liver microsomes. Biochem. Biophys. Res. Commun., 1982, 109, 813-8.
300. Bondy, S.C.; Naderi, S. Contribution of hepatic cytochrome P450 systems to the generation of reactive oxygen species. Biochem. Pharmacol., 1994, 48, 155-9.
301. Rashba-Step, J.; Cederbaum, A.I. Generation of reactive oxygen intermediates by human liver microsomes in the presence of NADPH or NADH. Mol. Pharmacol., 1994, 45, 150-7.
302. Das, J.; Roy, A.; Sil, P.C. Mechanism of the protective action of taurine in toxin and drug induced organ pathophysiology and diabetic complications: a review. Food Funct., 2012, 3, 1251-64.
303. Das, J.; Sil, P.C. Taurine ameliorates alloxan-induced diabetic renal injury, oxidative stress-related signaling pathways and apoptosis in rats. Amino Acids, 2012, 43, 1509-23.
304. Rashid, K.; Bhattacharya, S.; Sil, P.C. Protective role of Dsaccharic acid-1,4-lactone in alloxan induced oxidative stress in the spleen tissue of diabetic rats is mediated by suppressing mitochondria dependent apoptotic pathway. Free Radic. Res., 2012, 46, 240-52.
305. Rashid, K.; Das, J.; Sil, P.C. Taurine ameliorate alloxan induced oxidative stress and intrinsic apoptotic pathway in the hepatic tissue of diabetic rats. Food Chem. Toxicol., 2013, 51, 317-29.
306. Manna, P.; Das, J.; Ghosh, J.; Sil, P.C. Contribution of type 1 diabetes to rat liver dysfunction and cellular damage via activation of NOS, PARP, IkappaBalpha/NF-kappaB, MAPKs, and mitochondria-dependent pathways: Prophylactic role of arjunolic acid. Free Radic. Biol. Med., 2010, 48, 1465-84.
307. Manna, P.; Ghosh, J.; Das, J.; Sil, P.C. Streptozotocin induced activation of oxidative stress responsive splenic cell signaling pathways: protective role of arjunolic acid. Toxicol. Appl. Pharmacol., 2010, 244, 114-29.
308. Behl, C. Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches. Prog. Neurobiol., 1999, 57, 301-23.
309. Andrus, P.K.; Fleck, T.J.; Gurney, M.E.; Hall, E.D. Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem., 1998, 71, 2041-8.
310. Sinha, K.; Pal, P.B.; Sil, P.C. Cadmium (Cd(2+)) exposure differentially elicits both cell proliferation and cell death related responses in SK-RC-45. Toxicol. In vitro, 2014, 28, 307-18.
311. Ames, B.N.; Gold, L.S.; Willett, W.C. The causes and prevention of cancer. Proc. Natl. Acad. Sci. U. S. A.,1995, 92, 5258-65.
312. Orr, W.C.; Sohal, R.S. Extension of life-span by overexpression of superoxide dismutase and catalase in Drosophila melanogaster. Science, 1994, 263, 1128-30.
313. Pierce, G.B.; Parchment, R.E.; Lewellyn, A.L. Hydrogen peroxide as a mediator of programmed cell death in the blastocyst. Differentiation, 1991, 46, 181-6.
314. Bhattacharyya, S.; Ghosh, J.; Sil, P.C. Iron induces hepatocytes death via MAPK activation and mitochondria-dependent apoptotic pathway: beneficial role of glycine. Free Radic. Res., 2012, 46, 1296-307.
315. Sinha, K.; Das, J.; Pal, P.B.; Sil, P.C. Oxidative stress: the mitochondria-dependent and mitochondria-independent pathways of apoptosis. Arch. Toxicol., 2013, 87, 1157-80.
316. Manna, P.; Bhattacharyya, S.; Das, J.; Ghosh, J.; Sil, P.C. Phytomedicinal Role of Pithecellobium dulce against CCl(4)-mediated Hepatic Oxidative Impairments and Necrotic Cell Death. Evid. Based Complement. Alternat. Med., 2011, 2011, 832805.
317. Barouki, R.; Morel, Y. Repression of cytochrome P450 1A1 gene expression by oxidative stress: mechanisms and biological implications. Biochem. Pharmacol., 2001, 61, 511-6.
318. Morel, Y.; de Waziers, I.; Barouki, R. A repressive cross-regulation between catalytic and promoter activities of the CYP1A1 and CYP2E1 genes: role of H2O2. Mol. Pharmacol., 2000, 57, 1158-64.
319. Bhattacharyya, S.; Pal, P.B.; Sil, P.C. A 35 kD Phyllanthus niruri protein modulates iron mediated oxidative impairment to hepatocytes via the inhibition of ERKs, p38 MAPKs and activation of PI3k/Akt pathway. Food Chem. Toxicol., 2013, 56, 119-30.
320. Pal, P.B.; Pal, S.; Das, J.; Sil, P.C. Modulation of mercury-induced mitochondria-dependent apoptosis by glycine in hepatocytes. Amino Acids, 2012, 42, 1669-83.
321. Pal, P.B.; Sinha, K.; Sil, P.C. Mangiferin, a natural xanthone, protects murine liver in Pb(II) induced hepatic damage and cell death via MAP kinase, NF-kappaB and mitochondria dependent pathways. PLoS One, 2013, 8, e56894.
322. Pal, S.; Pal, P.B.; Das, J.; Sil, P.C. Involvement of both intrinsic and extrinsic pathways in hepatoprotection of arjunolic acid against cadmium induced acute damage in vitro. Toxicology, 2011, 283, 129-39.
323. Sarkar, A.; Das, J.; Manna, P.; Sil, P.C. Nano-copper induces oxidative stress and apoptosis in kidney via both extrinsic and intrinsic pathways. Toxicology, 2011, 290, 208-17.
324. Ghosh, J.; Das, J.; Manna, P.; Sil, P.C. Hepatotoxicity of di-(2-ethylhexyl)phthalate is attributed to calcium aggravation, ROSmediated mitochondrial depolarization, and ERK/NF-kappaB pathway activation. Free Radic. Biol. Med., 2010, 49, 1779-91.
325. Ghosh, J.; Das, J.; Manna, P.; Sil, P.C. Taurine prevents arsenicinduced cardiac oxidative stress and apoptotic damage: role of NFkappa B, p38 and JNK MAPK pathway. Toxicol. Appl. Pharmacol., 2009, 240, 73-87.
326. Gruenke, L.D.; Konopka, K.; Cadieu, M.; Waskell, L. The stoichiometry of the cytochrome P-450-catalyzed metabolism of methoxyflurane and benzphetamine in the presence and absence of cytochrome b5. J. Biol. Chem.,1995, 270, 24707-18.
327. Hlavica, P. On the function of cytochrome b5 in the cytochrome P-450-dependent oxygenase system. Arch. Biochem. Biophys.,1984, 228, 600-8.
328. Hlavica, P.; Lewis, D.F. Allosteric phenomena in cytochrome P450-catalyzed monooxygenations. Eur. J. Biochem., 2001, 268, 4817-32.
329. Yamazaki, H.; Johnson, W.W.; Ueng, Y.F.; Shimada, T.; Guengerich, F.P. Lack of electron transfer from cytochrome b5 in stimulation of catalytic activities of cytochrome P450 3A4. Characterization of a reconstituted cytochrome P450 3A4/NADPH-cytochrome P450 reductase system and studies with apo-cytochrome b5. J. Biol. Chem.,1996, 271, 27438-44.
330. Perret, A.; Pompon, D. Electron shuttle between membrane-bound cytochrome P450 3A4 and b5 rules uncoupling mechanisms. Biochemistry, 1998, 37, 11412-24.
331. Epstein, P.M.; Curti, M.; Jansson, I.; Huang, C.K.; Schenkman, J.B. Phosphorylation of cytochrome P450: regulation by cytochrome b5. Arch. Biochem. Biophys.,1989, 271, 424-32.
332. Mkrtchian, S.L.; Andersson, K.K. A possible role of cAMP dependent phosphorylation of hepatic microsomal cytochrome P450: a mechanism to increase lipid peroxidation in response to hormone. Biochem. Biophys. Res. Commun.,1990, 166, 787-93.
333. Davydov, D.R. Microsomal monooxygenase in apoptosis: another target for cytochrome c signaling? Trends Biochem. Sci., 2001, 26, 155-60.
334. Zhukov, A.; Ingelman-Sundberg, M. Relationship between cytochrome P450 catalytic cycling and stability: fast degradation of ethanol-inducible cytochrome P450 2E1 (CYP2E1) in hepatoma cells is abolished by inactivation of its electron donor NADPHcytochrome P450 reductase. Biochem. J.,1999, 340 ( Pt 2), 453-8.
335. Korsmeyer, K.K.; Davoll, S.; Figueiredo-Pereira, M.E.; Correia, M.A. Proteolytic degradation of heme-modified hepatic cytochromes P450: A role for phosphorylation, ubiquitination, and the 26S proteasome? Arch. Biochem. Biophys.,1999, 365, 31-44.
336. Murray, B.P.; Correia, M.A. Ubiquitin-dependent 26S proteasomal pathway: a role in the degradation of native human liver CYP3A4 expressed in Saccharomyces cerevisiae? Arch. Biochem. Biophys., 2001, 393, 106-16.
337. Das, J.; Ghosh, J.; Manna, P.; Sil, P.C. Protective role of taurine against arsenic-induced mitochondria-dependent hepatic apoptosis via the inhibition of PKCdelta-JNK pathway. PLoS One, 2010, 5, e12602.
338. Bhattacharyya, S.; Ghosh, S.; Sil, P.C. Amelioration of aspirin induced oxidative impairment and apoptotic cell death by a novel antioxidant protein molecule isolated from the herb Phyllanthus niruri. PLoS One, 2014, 9, e89026.
339. Ghosh, J.; Das, J.; Manna, P.; Sil, P.C. The protective role of arjunolic acid against doxorubicin induced intracellular ROS dependent JNK-p38 and p53-mediated cardiac apoptosis. Biomaterials, 2011, 32, 4857-66.
340. Pal, S.; Sil, P.C. A 43 kD protein from the leaves of the herb Cajanus indicus L. modulates doxorubicin induced nephrotoxicity via MAPKs and both mitochondria dependent and independent pathways. Biochimie, 2012, 94, 1356-67.
341. Sarkar, A.; Sil, P.C. Iron oxide nanoparticles mediated cytotoxicity via PI3K/AKT pathway: Role of quercetin. Food Chem. Toxicol., 2014.
342. Flora, K.; Hahn, M.; Rosen, H.; Benner, K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am. J. Gastroenterol., 1998, 93, 139-43.
343. Sheeja, K.; Kuttan, G. Ameliorating effects of Andrographis paniculata extract against cyclophosphamide-induced toxicity in mice. Asian Pac. J. Cancer Prev.,2006, 7, 609-14.
344. Murias, M.; Jodynis-Liebert, J.; Matlawska, I.; Bylka, W. Antioxidant activity of isocytisoside and extracts of Aquilegia vulgaris. Fitoterapia, 2005, 76, 476-80.
345. Sanmugapriya, E.; Venkataraman, S. Studies on hepatoprotective and antioxidant actions of Strychnos potatorum Linn. seeds on CCl4-induced acute hepatic injury in experimental rats. J. Ethnopharmacol., 2006, 105, 154-60.
346. Saraswat, B.; Visen, P.K.; Patnaik, G.K.; Dhawan, B.N. Ex vivo and in vivo investigations of picroliv from Picrorhiza kurroa in an alcohol intoxication model in rats. J. Ethnopharmacol.,1999, 66, 263-9.